ArticleJCO precision oncology2026
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAnal adenocarcinoma (AD) is a rare GI malignancy with no established standard treatment. Little is known about genomic alterations (GAs) and their therapeutic implications in advanced anal AD. Here, we compared the genomic profiles of advanced anal AD and advanced rectal AD.
methodsWe retrospectively extracted data from patients with advanced anal or rectal AD who underwent comprehensive genomic profiling (CGP) and were registered at the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) in Japan. We examined somatic GAs, microsatellite instability (MSI) status, and tumor mutation burden (TMB).
resultsFrom June 2019 to April 2023, 45 patients with anal AD and 1,915 patients with rectal AD were enrolled into the C-CAT database.
conclusionAdvanced anal AD exhibited a distinct genomic profile compared with advanced rectal AD. CGP is a useful approach for identifying druggable GAs in advanced anal AD to expand therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.